Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) has issued an announcement.
Lepu Biopharma Co., Ltd. has entered an exclusive licensing agreement with ArriVent BioPharma, Inc. to develop and commercialize its novel ADC candidate, MRG007, outside the Greater China region. This agreement allows ArriVent to leverage Lepu’s intellectual property for MRG007, a promising treatment for gastrointestinal cancers, potentially yielding up to $1.16 billion in milestone payments for Lepu. This partnership is expected to enhance Lepu’s global presence and maximize its pipeline and commercial value.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in China, operating in the biopharmaceutical industry. The company is involved in developing innovative medical solutions, particularly focusing on antibody drug conjugates (ADCs) for treating cancers.
YTD Price Performance: -9.54%
Average Trading Volume: 5,651,651
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$4.05B
See more insights into 2157 stock on TipRanks’ Stock Analysis page.